Literature DB >> 2023761

Management of intraretinal metallic foreign bodies without retinopexy in the absence of retinal detachment.

J S Ambler1, S M Meyers.   

Abstract

In the management of intraocular metallic foreign bodies impacting or embedded in the posterior retina but without retinal detachment, retinopexy can be difficult or dangerous because of surrounding retinal, subretinal, or choroidal hemorrhage, or the proximity of the foreign body to the optic disc and macula. The authors prospectively managed five such cases by pars plana vitrectomy and foreign body removal without intraoperative or postoperative retinopexy. Fluid gas exchange was performed in only one case. No attempt was made to create a posterior vitreous detachment in any of the cases. After follow-up, ranging between 8 and 35 months, all cases had attached retinas and chorioretinal adhesion around the foreign body site. None of the cases had preretinal macular fibrosis. Four of the five cases had a best corrected visual acuity of 20/20 or better. The other, an aphakic 3-year-old patient, was amblyopic. Spontaneous chorioretinal adhesion appears to obviate the need for retinopexy in these selected cases. The avoidance of retinopexy and fluid gas exchange may decrease the risk of retinal detachment and preretinal macular fibrosis.

Entities:  

Mesh:

Year:  1991        PMID: 2023761     DOI: 10.1016/s0161-6420(91)32284-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  2 in total

1.  Late onset of rhegmatogenous retinal detachments after successful posterior segment intraocular foreign body removal.

Authors:  D J Weissgold; P Kaushal
Journal:  Br J Ophthalmol       Date:  2005-03       Impact factor: 4.638

2.  Outcomes of surgery for posterior segment intraocular foreign bodies--a retrospective review of 17 years of clinical experience.

Authors:  Louisa Wickham; Wen Xing; Catey Bunce; Paul Sullivan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.